To include your compound in the COVID-19 Resource Center, submit it here.

NodThera parlays interest in inflammasome into Novo Ventures-led $55M series B

Novo Ventures has led a $55 million series B round for NodThera, a trans-Atlantic biotech operating in an area ripe for takeouts -- the inflammasome.

The biotech's lead program targets NLRP3, a target explored by three biotechs that have been acquired in the last three years. For the two deals with disclosed terms, each of the biotechs received at least $300

Read the full 608 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE